Lehi, Utah Hyagen Medical today announced that Founder and President Charles Meeker, Ph.D., Esq., has joined the Advisory Board of the American Academy of Peptide Medicine (AAPM), a national organization dedicated to advancing education, professional standards, and regulatory awareness throughout the peptide medicine community.
Meeker’s appointment reflects a shared commitment between Hyagen Medical and AAPM to promote regulatory clarity, strengthen professional education, and encourage transparent communication as peptide medicine, regenerative medicine, longevity science, and biologic innovation continue to evolve. While joining the Advisory Board is a professional milestone, Meeker believes the larger story is about the future of an industry experiencing unprecedented growth.
Innovation Is Accelerating. Education Must Keep Pace.
Over the past several years, public interest in peptide medicine, regenerative biologics, longevity science, and wellness medicine has expanded dramatically. Conversations that once took place primarily among physicians, researchers, and scientists are now happening on podcasts, social media, healthcare conferences, and inside clinics across the country.
Greater awareness creates opportunity. It also creates responsibility. As scientific discovery continues to advance, education, regulatory understanding, and professional communication must evolve alongside it. Without clear standards and accurate information, confusion can outpace understanding.
“The science is not what concerns me,” said Meeker. “Science is supposed to evolve. What truly concerns me is when public enthusiasm begins moving faster than public understanding. That’s where confusion starts. That’s where unrealistic expectations begin. And ultimately, that’s where patients can be put at risk.”
Why the American Academy of Peptide Medicine Matters
The American Academy of Peptide Medicine was established to help advance education, professional standards, and regulatory awareness throughout the peptide medicine industry. By bringing together physicians, scientists, educators, regulatory professionals, and industry leaders, AAPM creates opportunities for thoughtful discussion around emerging science, evolving regulatory expectations, and responsible professional communication.
Its mission reflects something many healthcare leaders recognize: long-term credibility is built through education, transparency, accountability, and a commitment to high professional standards. For Meeker, that mission closely aligns with Hyagen Medical’s own commitment to advancing regulatory clarity and professional education.
“We’ve always believed that trust is earned through transparency,” he said. “The future of regenerative medicine won’t be determined by who makes the biggest claims. It will be determined by who commits to the highest standards.”
Why Regulatory Education Has Become Increasingly Important
As regenerative medicine and peptide medicine continue to grow, regulatory education has become increasingly important for healthcare organizations seeking to operate responsibly. Federal agencies, including the FDA and FTC, have taken enforcement actions against organizations that marketed unproven regenerative medicine products or made claims that exceeded current regulatory requirements.
The lessons from these cases are not about assigning blame. They are about helping healthcare professionals better understand regulatory expectations, communicate accurately, and build lasting patient trust. “The vast majority of clinic owners are trying to do things the right way,” Meeker said. “Education provides clarity, and clarity builds confidence.”
Frequently Asked Questions
What is the American Academy of Peptide Medicine?
The American Academy of Peptide Medicine (AAPM) is a professional organization dedicated to advancing education, professional standards, and regulatory awareness. For more information, visit pepmed.com.
Why did Charles Meeker join the Advisory Board?
Meeker accepted the appointment because it aligns closely with Hyagen Medical’s commitment to regulatory clarity, professional education, and transparent communication.
About Charles Meeker, Ph.D., Esq.
Charles Meeker is the Founder and President of Hyagen Medical. As both a scientist and attorney, he advises healthcare organizations on biologic science, regulatory strategy, and responsible industry practices.
Learn More
Visit Hyagen Medical to explore educational resources and learn about the Hyagen Gold Standard Certification program. To connect with Charles Meeker, visit his LinkedIn profile.
Regenerative medicine is one of the fastest-moving beats in modern healthcare where innovation, regulation, patient safety, and marketing claims collide. If you're a journalist, producer, editor, or podcast host covering stem cells and biologics, you need credible sources fast, especially when you're on deadline.
That's why Hyagen Medical created a downloadable Media Kit a press-ready resource built to help you develop accurate angles, verify context, and book expert interviews without the usual back-and-forth.
What you'll find inside the Hyagen Medical Media Kit
The Hyagen Medical Media Kit is designed for speed, clarity, and accuracy. It includes:
- Approved Hyagen Medical overview (what Hyagen Medical is, and what it does in the regenerative medicine industry)
- Expert bio + credentials for Chuck Meeker (Ph.D., Esq.), Founder & President
- Suggested story angles + interview topics (regenerative medicine, FDA/FTC standards, ethical marketing, patient trust)
- Media statistics and impact highlights (reach and training footprint)
- Press-ready brand assets (logos + quick reference material)
- Direct contact info for interviews and media requests
"As Seen On": Chuck Meeker's media features
If you're looking for a credible expert voice who can translate complex stem cell and compliance issues into clear, usable commentary, the one-sheet inside the Media Kit includes Chuck's "As Seen On" section, featuring:
- Science Journal
- ABC4 News
- The Ultimate Assist
The one-sheet also notes an upcoming feature: Make America Great with Robert F. Kennedy Jr.
Why Hyagen Medical is relevant to your coverage
Hyagen Medical™ is positioned as a training and certification authority focused on regenerative medicine compliance, clinic education, and patient protection especially where the industry is vulnerable: claims, sourcing, transparency, and regulatory alignment.
From the Media Kit one-sheet highlights:
- 100+ clinics trained in FDA-compliant practices
- 19M+ media audience reached
- $1.2M+ in regulatory legal fees saved through compliance education and strategy
If your story touches enforcement, consumer protection, evolving standards, ethical marketing, or the difference between hype and evidence Hyagen Medical's Media Kit gives you a solid foundation fast.
Download the Hyagen Medical Media Kit (and book fast if you're on deadline)
You can download the Media Kit directly from Hyagen Medical's Media page. If you're working on a story and need quick turnaround, send your deadline and angle and we'll respond quickly.
Media Contact: [email protected]
Media Phone: 757-621-9319
Frequently Asked Questions
What is the Hyagen Medical Media Kit?
A downloadable press resource for journalists covering regenerative medicine, stem cell therapy regulation, clinic compliance, and patient safety.
Who is Chuck Meeker?
Chuck Meeker (Ph.D., Esq.) is Hyagen Medical's Founder and President, known for simplifying regenerative medicine compliance, ethical marketing, and regulatory strategy.
What's included in the Hyagen Medical press kit?
Press-ready bios, "As Seen On" media placements, story angles, fast facts, logos, and booking/contact info.
How do I request an interview with Hyagen Medical?
Use the media contact information in the Media Kit or reach out via the Media page contact pathway with your deadline and topic.
What topics can Hyagen Medical comment on?
The real state of stem cell clinics in the U.S., where hype ends and regulation begins, and how ethical transparency can rebuild patient trust in regenerative medicine.
FDA regulatory frameworks have not changed. At the same time, peptide substances remain under active federal review, and visibility is increasing.
FDA 503A Update: Peptides Remain Under Evaluation
The FDA's latest update to the 503A bulk drug substances list reinforces that many peptides are still within formal regulatory review processes, not approved for broad clinical use. Key highlights include updates across three categories:
- Category 1: Bulk drug substances under evaluation
- Category 2: Substances that raise significant safety concerns
- Category 3: Substances nominated without adequate support
Removal of multiple peptide substances from Categories 1 and 2 due to withdrawn nominations, including: BPC-157, Thymosin Beta-4 (TB-500), Melanotan II, GHK-Cu, KPV, MOTs-C, Semax, and Epitalon.
The update also confirms that the FDA will consult the Pharmacy Compounding Advisory Committee (PCAC) throughout 2026–2027 regarding potential inclusion of these substances on the 503A bulks list. These updates do not indicate approval, expanded access, or regulatory clearance. They reflect ongoing evaluation within established FDA compounding and drug review frameworks.
What This Means for Peptide Regulation
For clinics and providers, the implications are clear:
- Peptide regulation remains governed by existing FDA pathways
- Section 503A compounding rules still apply
- Marketing, classification, and communication standards have not changed
Public attention regardless of source does not alter what substances can be compounded, how products can be described, or what claims can be made to patients. Regulatory status is determined through FDA review not public discourse.
The Growing Risk: Visibility Without Alignment
As peptides re-enter public conversation, Hyagen Medical is observing a widening gap between what is being discussed publicly and what is permitted under current regulation. This gap creates measurable risk for clinics:
- Non-compliant marketing language
- Misclassification of compounded substances
- Patient communication that exceeds regulatory boundaries
Increased visibility may lead to increased scrutiny particularly in how clinics communicate about peptides.
The Hyagen Medical Standard: Compliance-First Education and Distribution
Hyagen Medical operates as a compliance-first partner to clinics nationwide, providing:
- Training aligned with FDA regulatory frameworks, including 503A compounding requirements
- Structured, compliant communication strategies
- Distribution standards focused on sourcing transparency and clinical integrity
The company's framework is grounded in a clear principle: Clarity in mechanism. Precision in language. Accountability in practice.
Industry Leadership at the Regulatory Level
Hyagen Medical's presence in Washington, D.C. reflects its commitment to engaging in ongoing regulatory dialogue as the peptide and biologics landscape evolves. Founder and President Chuck Meeker brings a dual background in science and law, providing a practical perspective on how clinics can operate within existing frameworks.
"As attention increases, the need for accuracy becomes more important not less. This is not a moment of expanded permission. It is a moment that requires clear understanding of what is allowed today." Chuck Meeker
A Call to Clinics: Align Before Enforcement Increases
Hyagen Medical advises clinics to approach this environment with discipline. The clinics best positioned moving forward will be those that:
- Understand FDA 503A compounding regulations
- Communicate within clearly defined boundaries
- Align operations with current not assumed regulatory standards
Hyagen Medical works with clinics across the United States to provide the education, structure, and support needed to operate compliantly within the evolving peptide and regenerative medicine landscape. Visit www.hyagenmedical.com to learn more.
Media Contact: Carrie Hill, Hyagen Medical Press & Communications [email protected]
Lehi, UT February 10, 2026 FDA compliance for regenerative medicine clinics is becoming the defining factor between sustainable growth and regulatory exposure. As patient demand for stem cell therapy and regenerative biologics expands nationwide, so does scrutiny from regulators, payment processors, and certification bodies. Clinics operating in this space must now demonstrate clear alignment with FDA 21 CFR Part 1271, 361 HCT/P standards, and compliant patient communication practices.
To address this growing need, Hyagen Medical has launched a National FDA Compliance and Education Initiative designed to help regenerative medicine clinics reduce regulatory risk, strengthen documentation systems, and elevate patient education standards. This initiative positions compliance not as a restriction but as a competitive advantage.
"Regenerative medicine doesn't need louder voices it needs clearer ones. Stem cells are politically agnostic. The real work is helping providers and patients understand what is compliant, ethical, and accurate." Chuck Meeker, Ph.D., Esq., Founder of Hyagen Medical
Why this matters now
As regenerative medicine becomes more visible to consumers, clinics face growing pressure to balance innovation with compliance. Confusion around appropriate claims, sourcing language, and regulatory boundaries has increased risk across the industry for providers and patients alike. Hyagen Medical was built to address that gap by standardizing compliance education and supporting transparent, well-documented patient conversations grounded in existing FDA frameworks.
"The biggest risk we see isn't innovation it's misinformation. When education is missing, trust erodes. Our role is to help clinics lead with clarity before problems arise." Chuck Meeker
Compliance-first as a credibility engine
Hyagen Medical works at the intersection of regulatory guidance, provider training, and patient-facing education. Its compliance-first model helps clinics:
- Navigate FDA regulatory boundaries with confidence
- Reduce exposure to risk from misleading claims or noncompliant marketing
- Strengthen informed consent and patient understanding
- Build long-term credibility in a rapidly evolving biologics landscape
Rather than treating regulation as a constraint, Hyagen Medical positions compliance as the foundation for sustainable growth in regenerative medicine.
Politically neutral, education-driven by design
Hyagen Medical maintains a deliberately neutral stance in public discourse, emphasizing that regenerative medicine and stem cell science are not political issues, but matters of patient safety, ethical sourcing, and regulatory clarity. By prioritizing accurate language, transparent education, and adherence to FDA guidance, Hyagen Medical aims to elevate both industry standards and public trust.
Product alignment and regulatory clarity
In addition to education and consulting, Hyagen Medical distributes regenerative biologics, including HCT/P allograft products positioned under FDA “361 HCT/P” and AATB guidelines. Products are clearly described as minimally manipulated and intended for homologous use only reinforcing the company's commitment to compliant positioning and responsible clinical use.
Outcomes Hyagen Medical aims to support
- Clearer, more consistent patient education and informed consent
- Increased provider confidence navigating regulatory frameworks
- Reduced regulatory and reputational risk across practices
- Stronger, credibility-led adoption of regenerative medicine therapies
For journalists covering regenerative medicine, biologics, or health policy
Hyagen Medical and Founder Chuck Meeker are available for expert commentary on:
- FDA compliance and regenerative medicine regulation
- Patient education and informed consent best practices
- Ethical implementation of stem cell and biologics therapies
- Separating science from misinformation in public health conversations
This release addresses the FDA compliance requirements for regenerative medicine clinics and patient education. Interview requests are available upon request.
About Hyagen Medical
Hyagen Medical is a regenerative medicine compliance and education company headquartered in Lehi, Utah. Founded by Chuck Meeker, the company supports healthcare providers nationwide through FDA-aligned training, regulatory consulting, biologics distribution, and patient education systems designed to promote ethical, compliant, and transparent regenerative medicine practices.
Press inquiries: Carrie Hill, Head of Public Relations media [at] hyagenmedical.com
Marketing regenerative medicine is high-risk if your claims outpace evidence or policy. Here's how to stay educational, compliant, and discoverable.
In this Grow Smarter podcast interview with Hyagen Medical Founder Chuck Meeker, host Andrew Hong, Founder of Tobe Agency, dives deeper into Hyagen Medical's practical, compliance-first training guide for regenerative medicine brands: including safer messaging, claim boundaries, Google policy realities, and PR strategies that build trust.
If you work in regenerative medicine, you already know the truth: marketing is where innovation meets scrutiny. The minute your website language reads like a promise to treat a disease, you're no longer "just educating" you may be signaling product intent in a way regulators and platforms evaluate aggressively. This guide is built for clinics, founders, marketers, and journalists covering the space. It's compliance-first: not how to "evade" rules but how to communicate responsibly, earn trust, and stay discoverable.
Important note: This is general information, not legal advice. Regenerative medicine regulation is complex. Consult qualified FDA/regulatory counsel for your specific products, procedures, sourcing, and claims.
Why Stem Cell Marketing Gets Flagged So Easily
1. The FDA looks at what you imply, not just what you sell
FDA guidance makes clear that labeling and advertising can reflect a company's "objective intent," including whether something is being promoted for non-homologous use or outside criteria for certain regulatory pathways. Translation: your website copy, blog posts, patient testimonials, videos, and even "conditions we treat" pages can become part of how your intent is interpreted.
2. Enforcement is real and public
FDA has issued warning letters and notices to companies marketing unapproved or noncompliant stem-cell-related offerings, often citing disease claims and unapproved product marketing.
3. Google and other platforms have "speculative/experimental" filters
Google Ads restricts many promotions for speculative or experimental treatments, and it draws hard lines around what can be directly promoted versus what can be purely educational/informational. Industry groups have also raised concerns that "educational" language could be misused so platforms watch intent and landing page behavior closely.
4. The FTC cares about substantiation
Separately from FDA, the FTC expects marketers to have competent and reliable scientific evidence for health-related claims and to communicate limitations clearly when science is emerging.
The Compliance-First Messaging Framework (Use This)
Step 1: Replace "Treatments for Conditions" with "Education + Eligibility"
High-risk: "We treat arthritis, spinal stenosis, neuropathy, autoimmune disease, and more." · "Avoid surgery with stem cells." · "Cures inflammation and chronic pain."
Lower-risk, more compliant positioning:
- "Regenerative medicine education and clinical consultation."
- "Patient eligibility and options review (including risks, benefits, evidence, and alternatives)."
- "Orthobiologics: what the research says, what's experimental, and what patients should ask."
Rule of thumb: You can educate about a topic; you should be extremely cautious about promising outcomes especially for named diseases.
Step 2: Use "Evidence Language," Not "Outcome Language"
Swap "Proven to regenerate cartilage" for "Research is ongoing. Some studies suggest potential benefits for certain orthopedic indications, and results vary." Swap "Guaranteed relief" for "Outcomes vary by patient, protocol, diagnosis, and overall health. A consult is required to determine candidacy." This aligns with what regulators and platforms expect: clarity, uncertainty disclosure, and avoidance of overpromising.
Step 3: Keep Testimonials and Stories "Non-Clinical"
Testimonials are powerful but they are also high-risk if they imply disease treatment or guaranteed outcomes. Safer testimonial structures:
- Experience-focused: scheduling, education, informed consent, staff professionalism
- Decision-focused: "I appreciated learning risks and alternatives before choosing a path."
- Recovery-focused without diagnosis claims: "I felt supported and had a positive experience."
- Avoid: named diseases + "it fixed/cured/treats" language.
Google Ads Reality: What's Most Likely to Work
Google's policy allows ads for FDA approved/licensed cell or gene therapies under specific conditions, and it also allows content that is exclusively educational or informational, regardless of approval status. So for many regenerative medicine brands, the practical path is the "Education-First Funnel": Ad → Educational landing page → Consult request (carefully framed).
Examples of education-first topics that can drive traffic without triggering immediate policy issues:
- "Stem cells vs PRP vs exosomes: what they are and what evidence exists"
- "Understanding FDA terminology: minimal manipulation, homologous use, HCT/P basics"
- "Questions every patient should ask before traveling for treatment"
- "How to evaluate a clinic's sourcing, protocols, and informed consent"
Avoid: direct ads that promise treatment outcomes for specific conditions, or landing pages that read like a disease-treatment menu.
A Safer Website Structure for Regenerative Medicine Brands
If you want search traffic without the "banned" triggers, structure your site like a resource center, not a claims page. Recommended site architecture:
- Start Here (Patient Education Hub): definitions, risks, realistic expectations, alternatives
- Regulatory & Safety Page: FDA language overview, compliance posture, sourcing transparency
- Evidence Library: summaries + links to peer-reviewed research, with clear "limitations" framing
- Consultation Page: what a consult includes, how eligibility is determined, who should not proceed
- Media Page (for journalists): expert bios, interview topics, prior media, data points, contact
"Red Flag" Phrases That Commonly Trigger Scrutiny
Avoid or heavily qualify: "cure," "treat," "heal," "reverse," "regrow," "guarantee," "FDA approved" (unless it truly is, and for that exact product/indication), "proven," "clinically verified," "no risk," "no side effects," and long lists of diseases/conditions presented as services. Enforcement actions and public notices often cite disease-treatment marketing claims as a key issue.
The PR Strategy That Builds Authority (and Protects You)
If ads are restricted, PR and content often become the most durable growth engine. What works in regenerative medicine PR:
- Journalist-friendly explainers (science + policy + patient safety)
- Expert commentary on FDA language, enforcement trends, and consumer risk
- Data transparency: what you track, what you don't claim, what you disclose
- Myth vs reality series: medical tourism, exaggerated promises, and how patients can protect themselves
This is also where Hyagen Medical is positioned: education that protects patients and helps clinics communicate responsibly.
Quick Compliance Checklist (Save This)
Before publishing any page, video, or ad:
- ✅ Are we educating, not promising outcomes?
- ✅ Are we avoiding disease-treatment menus and "guarantee" language?
- ✅ Do we disclose uncertainty where science is emerging?
- ✅ Are testimonials non-clinical and non-diagnostic?
- ✅ Does the page read like a resource, not a sales pitch for treating conditions?
- ✅ If running ads, is the landing page exclusively educational?
Want a Media Question Answered on Hyagen Medical?
Hyagen Medical exists to bring clarity to regenerative medicine for patients, clinics, and journalists navigating science, safety, and regulation. Want your question featured or need expert commentary for a story? Email us and join the conversation.
Journalists covering regenerative medicine, FDA enforcement, biotech policy, or patient safety: this episode is built for your beat.
On The Ultimate Assist, John Stockton and Ken Ruettgers sit down with Dr. Harry Adelson (Docere Clinics) and Dr. Chuck Meeker (PhD scientist + patent attorney) to unpack what's really happening inside the stem cell and birth-tissue conversation clinically, legally, and culturally.
We explore bone marrow vs. birth tissue, the innovation-vs.-regulation collision, how FDA language restrictions shape what clinics can say, and the real-world outcomes that keep patients looking for alternatives to surgery. We also address medical tourism, hype vs. evidence, and the public health ripple effects that keep this industry under a microscope.
If you're producing a story, building a segment, or looking for expert commentary, this is a strong starting point.
Want your question featured (or need a quick quote/source)? Email us and join the conversation.
Regenerative medicine is changing the conversation around healthcare. As more patients seek information about peptides, birth tissue-derived products, and other regenerative technologies, the industry is experiencing tremendous growth. But with that growth comes an equally important responsibility: ensuring that patient safety, scientific integrity, and regulatory compliance remain at the center of every conversation.
That was the focus of Hyagen Medical Founder Chuck Meeker, Ph.D., Esq., during his recent appearance on ABC4’s Good Things Utah, where he discussed the importance of helping patients make informed decisions and helping clinics understand today’s regulatory landscape.
At Hyagen Medical, we believe innovation should always be accompanied by education.
Why Patient Safety Must Come Before Hype
Interest in regenerative medicine has expanded rapidly over the past several years. Patients are researching new technologies online, hearing success stories on podcasts, and seeing an increasing number of clinics offering regenerative medicine services.
Unfortunately, public awareness has grown faster than public understanding. Many patients don’t know what questions to ask before selecting a clinic. Others may assume every clinic follows the same quality standards or operates under the same compliance framework.
That’s why education matters. Patient safety begins long before someone walks into an exam room. It starts with accurate information, transparent communication, and choosing providers who value science, ethics, and regulatory compliance.
Education Empowers Better Decisions
During his ABC4 interview, Chuck emphasized that patients deserve more than marketing—they deserve education. Understanding the differences between peptides, birth tissue-derived products, regulatory classifications, and clinic standards allows patients to have more informed conversations with their healthcare providers.
An educated patient is better equipped to ask important questions, including:
- Where are your products sourced?
- Are your products manufactured under applicable FDA regulations?
- How do you educate patients about your products?
- How do you ensure your clinic follows current regulatory standards?
- What quality assurance processes are in place?
These conversations help create transparency while strengthening trust between patients and providers.
FDA Compliance Is a Patient Safety Issue
One of the biggest misconceptions in regenerative medicine is that compliance is simply paperwork. In reality, compliance exists to help protect patients.
Federal regulatory frameworks establish important standards for how certain birth tissue-derived products are manufactured, distributed, and marketed. Understanding those requirements helps clinics operate responsibly while reducing unnecessary regulatory risk.
Responsible clinics recognize that compliance isn’t a barrier to innovation. It’s the foundation for sustainable growth, patient confidence, and long-term credibility.
Building a Higher Standard for Clinics
At Hyagen Medical, our mission extends beyond supplying products. We are committed to helping clinics build compliant, transparent, and patient-centered practices through education, operational guidance, and regulatory clarity.
Our work focuses on helping healthcare providers:
- Better understand current FDA regulatory frameworks
- Strengthen compliant patient communication
- Improve operational integrity
- Build greater patient trust through transparency
- Stay informed as regulatory expectations continue to evolve
When clinics prioritize education alongside compliance, everyone benefits.
Why Responsible Communication Matters
The language used in regenerative medicine matters. Patients deserve clear, honest communication that explains products accurately without creating unrealistic expectations.
At Hyagen Medical, we believe healthcare communication should always be grounded in scientific integrity and responsible education. Our commitment is to help clinics communicate clearly, ethically, and within current regulatory frameworks while empowering patients with information they can trust.
Our Mission
Watching the regenerative medicine industry evolve has been inspiring. The opportunity to improve patient education, elevate professional standards, and encourage responsible innovation has never been greater. Hyagen Medical exists to help move that mission forward.
We are committed to creating meaningful dialogue around patient safety, clinical integrity, regulatory clarity, and transparent communication because these principles should never be optional in healthcare. As public interest in regenerative medicine continues to grow, so does our responsibility to ensure that innovation is matched with education, accountability, and trust.
Download the guide here to go deeper on building confidence through science, education, and integrity.
Thank You to ABC4
We are grateful to ABC4’s Good Things Utah, Producer Krystal Gates, George Severson, and the entire production team for helping bring this important conversation to viewers across Utah. Public education plays an essential role in strengthening healthcare, and we’re honored to contribute to that discussion.
Looking Ahead
The future of regenerative medicine depends on more than scientific advancement. It depends on informed patients. It depends on responsible clinics. It depends on transparent communication. And it depends on organizations willing to raise the standard for an entire industry. At Hyagen Medical, that is the work we’re committed to every day.
Learn More
Whether you’re a patient looking to ask better questions or a clinic seeking trusted education and regulatory guidance, Hyagen Medical is committed to supporting a safer, more transparent future for regenerative medicine. Explore our educational resources, clinic compliance solutions, and patient guides to learn more about building confidence through science, education, and integrity.
™
